Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes

Journal of Antimicrobial Chemotherapy

Volumn 56, Issue 6, 2005, Pages 1130-1133

  Al Lahham, Adnan ^a   De Souza, Noel J ^b   Patel, Mahesh ^b   Reinert, Ralf René ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Wockhardt Research Centre   (India)

Author keywords

Fluoroquinolones; Germany; Pneumococcus; Resistance

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 8 METHOXY 7 (4 AMINO 3,3 DIMETHYLPIPERIDIN 1 YL) 1,4 DIHYDRO 4 OXOQUINOLINE 3 CARBOXYLIC ACID; 9 FLUORO 6,7 DIHYDRO 8 (4 HYDROXYPIPERIDIN 1 YL) 5 METHYL 1 OXO 1H,5H BENZO[I,J]QUINOLIZINE 2 CARBOXYLIC ACID; AMOXICILLIN; CEFOTAXIME; CIPROFLOXACIN; CLARITHROMYCIN; CLINAFLOXACIN; CLINDAMYCIN; DALFOPRISTIN PLUS QUINUPRISTIN; ERYTHROMYCIN; GATIFLOXACIN; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TEICOPLANIN; TELITHROMYCIN; TETRACYCLINE; UNCLASSIFIED DRUG; VANCOMYCIN; WCK 1152; WCK 1153; WCK 771;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DILUTION; DRUG POTENCY; DRUG STRUCTURE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES;

ANTI-BACTERIAL AGENTS; BLOOD; BRONCHOALVEOLAR LAVAGE FLUID; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; HUMANS; MICROBIAL SENSITIVITY TESTS; PHARYNGITIS; PIPERIDINES; PNEUMOCOCCAL INFECTIONS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; TONSILLITIS; WOUNDS AND INJURIES;

EID: 29444454501     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dki361     Document Type: Article

References (10)

1. Reinert RR, Reinert S, van der Linden M et al. Antimicrobial susceptibility of Streptococcus pneumoniae in eight European countries from 2001 to 2003. Antimicrob Agents Chemother 2005 49: 2903-13.
2. Munoz R, De La Campa AG. ParC subunit of DNA topoisomerase IV of Streptococcus pneumoniae is a primary target of fluoroquinolones and cooperates with DNA gyrase A subunit in forming resistance phenotype. Antimicrob Agents Chemother 1996 40: 2252-7.
3. Janoir C, Zeller V, Kitzis MD et al. High-level fluoroquinolone resistance in Streptococcus pneumoniae requires mutations in parC and gyrA. Antimicrob Agents Chemother 1996 40: 2760-4.
4. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement, M100-S15. CLSI, Wayne, PA, USA, 2005.
5. Reinert RR, Franken C, van der Linden M et al. Molecular characterisation of macrolide resistance mechanisms of Streptococcus pneumoniae and Streptococcus pyogenes isolated in Germany, 2002-2003. Int J Antimicrob Agents 2004 24: 43-7.
6. Reinert RR, Lütticken R, Al-Lahham A. High-level fluoroquinolone resistance in a clinical Streptococcus pyogenes isolate in Germany. Clin Microbiol Infect 2004 10: 659-62.
7. Janoir C, Varon E, Kitzis MD et al. New mutation in ParE in a pneumococcal in vitro mutant resistant to fluoroquinolones. Antimicrob Agents Chemother 2001 45: 952-5.
8. Bozdogan B, Esel D, Whitener C et al. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother 2003 52: 864-8.
9. Appelbaum PC, Pankuch GA, Bozdogan B et al. Activity of the new quinolone WCK 771 against pneumococci. Clin Microbiol Infect 2005 11: 9-14.
10. Gupte SV, Patel MV, Upadhyay DJ et al. WCK 1152 & WCK 1153 - novel chiral fluoroquinolones (FQ) with attractive antistaphylococcal features. In: Abstracts of the Forty-third Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2003. Abstract F-433, p. 227. American Society for Microbiology, Washington, DC, USA.